Scorpion Therapeutics, Inc. licensed rights to two next-generation epidermal growth factor receptor (EGFR) inhibitors for lung cancer to the French pharmaceutical company Pierre Fabre in a deal that will help the oncology start-up advance multiple programs in the cash-constrained environment for biotechs.
The companies announced the co-development and commercialization agreement on 4 April, with Pierre Fabre gaining rights to STX-721 and STX-241 in certain geographies in exchange for $65m up front. Scorpion...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?